Orchestra BioMed Holdings, Inc. OBIO
NASDAQ
| 09/30/2026 | 06/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 3.41% | -20.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 3.41% | -20.00% | |||
| Cost of Revenue | 12.00% | -21.88% | |||
| Gross Profit | 0.00% | -19.23% | |||
| SG&A Expenses | -3.50% | -8.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.20% | 1.16% | |||
| Operating Income | -4.20% | -1.27% | |||
| Income Before Tax | 21.07% | -14.81% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 21.07% | -14.81% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 21.07% | -14.81% | |||
| EBIT | -4.20% | -1.27% | |||
| EBITDA | -4.20% | -1.25% | |||
| EPS Basic | 19.53% | -14.37% | |||
| Normalized Basic EPS | -3.30% | -2.01% | |||
| EPS Diluted | 19.53% | -14.37% | |||
| Normalized Diluted EPS | -3.30% | -2.01% | |||
| Average Basic Shares Outstanding | 1.27% | 1.74% | |||
| Average Diluted Shares Outstanding | 1.27% | 1.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||